Caretek signs ImplaJect feasibility study agreement:
This article was originally published in Clinica
Needle-free drug delivery developer Caretek Medical today signed an agreement with an undisclosed "major global pharmaceutical company" to perform a feasibility study of its ImplaJect system. The study will focus on whether the ImplaJect device can inject a solid dose formulation of one of the pharmaceutical company's protein based drugs, which is currently given to patients in liquid form, using a traditional needle and syringe. The agreement follows Oxford, UK-based Caretek's £2.1m ($3.7m) capital-raising success in December 2005.